PDF icon Download PDF
Klin Monbl Augenheilkd 2008; 225(6): 555-563
DOI: 10.1055/s-2007-963747
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Gibt es eine medikamentöse Therapie der altersbedingten Makuladegeneration? - Derzeitiger Stand und neue therapeutische Ansätze

Is There a Drug Therapy for Age-Related Macular Degeneration? - Current Status and New Therapeutic ApproachesA. J. Augustin1 , I. Offermann1
  • 1Augenklinik - Klinikum Karlsruhe
Further Information

Publication History

Eingegangen: 9.10.2007

Angenommen: 9.11.2007

Publication Date:
02 June 2008 (online)

Also available ateRef
   Permissions and Reprints
Preview

Zusammenfassung

Die altersbedingte Makuladegeneration (AMD), in der westlichen Welt eine der führenden Ursachen für Erblindungen (im Sinne des Gesetzes) im höheren Alter, wird unterteilt in eine häufigere (ca. 85 % der Fälle) trockene und eine feuchte Form. Alterungsprozesse führen bei der trockenen AMD zu Ablagerungen von zellulären Abbauprodukten im Bereich des retinalen Pigmentepithels und der Bruch’schen Membran mit der Folge degenerativer Veränderungen. Die chorioidale Neovaskularisation (CNV) verursacht bei der feuchten AMD eine rasch progrediente Minderung des zentralen Sehvermögens. Komplexe Prozesse wie Hypoxie und/oder Entzündungsreaktionen führen über eine erhöhte Expression von angiogenen Signalmolekülen zur Entstehung einer CNV. Dabei erscheint vor allem die Ausschüttung des vaskulären endothelialen Wachstumsfaktors (vascular endothelial growth factor [VEGF]) eine besondere Rolle zu spielen. Verschiedene monotherapeutische Ansätze wie photodynamische Therapie oder die intravitreale Gabe von VEGF-Inhibitoren sind mittlerweile zugelassen oder befinden sich im Endstadium der klinischen Erprobung. Die klinischen Ergebnisse bzw. die Notwendigkeit häufiger Behandlungen lassen eine Monotherapie langfristig als nichtpraktikabel erscheinen. Der Fokus zukünftiger Entwicklungen wird daher in Analogie zur Onkologie auf der Untersuchung von Kombinationsstrategien liegen, die sowohl die Pathogenese der Erkrankung wie auch Begleiteffekte der einzelnen Therapieansätze berücksichtigen müssen.

Abstract

Age-related macular degeneration (AMD) is the major cause of legal blindness in society today. In dry AMD age-related changes in Bruch’s membrane and RPE result in the accumulation of cell debris with consequent degeneration. In the less common but more aggressive form, wet AMD, hypoxia and inflammation lead to an up-regulation of different growth factors such as VEGF resulting in formation of choroidal neovascularisation. Different therapeutic modalities have evolved to address this problem. Examples are photodynamic therapy to eradicate choroidal neovascularisation (CNV) via a physiochemical reaction or intravitreal application of anti-VEGF agents to stop leakage of fluid from the same CNV. The overall results have been either disappointing or not practical because of the necessity of chronic treatment. The treatment goal continues to evolve to that already realised in oncology which is for a cure. This mandates the investigation of combination strategies. Combination strategies should focus on utilising the differing mechanisms of action on the pathogenesis of the disease all the while minimising the side effects of the individual therapeutic agents.

Schlüsselwörter

AMD - Zytokine - Kombinationstherapie

Key words

AMD - cytokines - combination therapy

Literatur

  • 1 Abdel-Meguid A, Lappas A, Hartmann K. et al . One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration.  Br J Ophthalmol. 2003;  87 615-621
    Search in Google Scholar
  • 2 Adamis A P, Shimra D T, Tolentino M J. et al . Inhibition of VEGF prevents ocular neovascularisation in a non-human primate.  Arch Ophthalmol. 1996;  114 66-71
    Search in Google Scholar
  • 3 Age-related eye disease study research group . A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss.  Arch Opthalmol. 2001;  119 1417-1436
    Search in Google Scholar
  • 4 Apte R S, Barreiro R A, Duh E. et al . Stimulation of neovascularization by the anti-angiogenetic factor PEDF.  Invest Ophthalmol Vis Sci. 2004;  45 4491-4497
    Search in Google Scholar
  • 5 Augustin A J, D’Amico D J, Mieler W F. et al . Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal chorodial neovascularization in patients with age-related macular degeneration.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 9-12
    Search in Google Scholar
  • 6 Augustin A J, Dick H B, Offermann I. et al . The significance of oxidative mechanisms in diseases of the retina.  Klin Monatsbl Augenheilkd. 2002;  219 631-643
    Search in Google Scholar
  • 7 Augustin A J, Offermann I. Emerging drugs for age-related macular degeneration.  Expert Opin Emerging Drugs. 2006;  11 725-740
    Search in Google Scholar
  • 8 Augustin A J, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration. Verteperfin PDT, bevacizumab and dexamethasone.  Retina. 2007;  27 133-140
    Search in Google Scholar
  • 9 Augustin A J, Schmidt-Erfurth U. Verteporfin therapy and triamcinolone convergent modes of action for treatment of neovascular age-related macular degeneration.  Eur J Ophthalmol. 2006;  16 824-834
    Search in Google Scholar
  • 10 Augustin A J, Schmidt-Erfurth U. Photodynamic therapy with Verteporfin combined with intravitreal Triamcinolone in occult choroidal neovascularization secondary to age-related macular degeneration.  Am J Ophthalmol. 2006;  141 638-645
    Search in Google Scholar
  • 11 Augustin A J, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.  Ophthalmology. 2006;  113 14-22
    Search in Google Scholar
  • 12 Augustin A J. Change of treatment paradigms for wet age-related macular degeneration.  European Pharmacotherapy. 2006;  1 30-33
    Search in Google Scholar
  • 13 Avery R L, Pieramici D J, Rabena M D. et al . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.  Ophthalmology. 2006;  113 363-372
    Search in Google Scholar
  • 14 Baird P N, Guida E, Chu D T. et al . The epsilon2 and epsilon4 alleles of the apoliopoprotein gene are associated with age-related macular degeneration.  Invest Ophthalmol Vis Sci. 2004;  45 1311-1315
    Search in Google Scholar
  • 15 Barak A, Hauser D, Yipp P. et al . A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration.  Br J Radiol. 2005;  78 827-831
    Search in Google Scholar
  • 16 Barouch F C, Miller J W. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularisation from age-related macular degeneration.  Internat Ophthalmol Clin. 2004;  44 23-30
    Search in Google Scholar
  • 17 Beatty S, Boulton M, Henson D. et al . Macular pigment and age-related macular degeneration.  Br J Ophthalmol. 1999;  83 867-877
    Search in Google Scholar
  • 18 Beatty S, Koh H, Phil M. et al . The role of oxidative stress in the pathogenesis of age-related macular degeneration.  Surv Ophthalmol. 2000;  45 115-134
    Search in Google Scholar
  • 19 Bressler S B, Bressler N M, Sarks S H. et al .Age-related macular degeneration: nonneovascular early AMD, intermediate AMD and geographic atrophy. Ryan SJ St. Louis; Mosby 2006 2: 1041-1074
    Search in Google Scholar
  • 20 Bressler S B, Maguire M G, Bressler N M. The Macular Photocoagulation Study Group. . Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration.  Arch Ophthalmol. 1990;  108 1442-1447
    Search in Google Scholar
  • 21 Brown D M, Kaiser P K, Michels M. et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1432-1434
    Search in Google Scholar
  • 22 Buch H, Vinding T, La Cour M. et al . Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study.  Acta Ophthalmol Scand. 2005;  83 409-418
    Search in Google Scholar
  • 23 Cebe-Suarez S, Zehnder-Fjallmann A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships.  Cell Mol Life Sci. 2006;  63 601-615
    Search in Google Scholar
  • 24 Challa J, Gillies M, Penfold P. et al . Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.  Aust N Zeal J Ophthalmol. 1998;  26 277-281
    Search in Google Scholar
  • 25 Clemons T E, Milton R C, Klein R. et al . Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report no. 19.  Ophthalmology. 2005;  112 533-539
    Search in Google Scholar
  • 26 D’Amico D J. VEGF inhibition study in ocular neovascularization (V. I. S. I. O.N.) Clinical Trial Group . VEGF inhibition study in neovascularization (VISION): second year efficacy data.  Invest Ophthalmol Vis Sci. 2005;  46 E-Abstract 2309
    Search in Google Scholar
  • 27 Danis R P, Ciulla T A, Pratt L M. et al . Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.  Retina. 2000;  20 244-250
    Search in Google Scholar
  • 28 De Faller J M, Clark A F. A new pharmacological treatment for angiogenesis. Taylor HR Pterygium The Hague; Kugler Publications 2000: 159-181
    Search in Google Scholar
  • 29 Eckardt C, Eckardt U, Conrad H G. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration.  Graefes Arch clin Exp Ophthalmol. 1999;  237 313-325
    Search in Google Scholar
  • 30 Eyetech Study Group . Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularisation secondary to age-related macular degeneration: phase II study results.  Ophthalmology. 2003;  110 979-986
    Search in Google Scholar
  • 31 Eyetech Study Group . Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.  Retina. 2002;  22 143-152
    Search in Google Scholar
  • 32 Fabbro D, Ruetz S, Bodis S. et al . PCK42a protein kinase inhibitor with a broad therapeutic potential.  Anticancer Drug Des. 2000;  15 17-28
    Search in Google Scholar
  • 33 Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress.  Endocrine Reviews. 2004;  25 581-611
    Search in Google Scholar
  • 34 Folkman J. Role of angiogenesis in tumor growth and metastasis.  Semin Oncol. 2002;  29 15-18
    Search in Google Scholar
  • 35 Foran S, Wang J J, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study.  Ophthalmic Epidemiol. 2003;  10 215-225
    Search in Google Scholar
  • 36 Frank R N. Growth factors in age-related macular degeneration: pathogenic and therapeutic implications.  Ophthalmic Res. 1997;  29 341-353
    Search in Google Scholar
  • 37 Fung A E, Lalwani G A, Rosenfeld P J. et al . An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.  Am J Ophthalmol. 2007;  143 566-583
    Search in Google Scholar
  • 38 Gaudreault J, Fei D, Rusit J. et al . Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.  Invest Ophthalmol Vis Sci. 2005;  46 726-733
    Search in Google Scholar
  • 39 Genentech. Lucentis® (ranibizumab injection) prescribing information. San Francisco; Genentech 2006 http://www.gene.com/gene/products/information/tgr/lucentis/index.jsp (Accessed 2006 Feb 23)
    Search in Google Scholar
  • 40 Gragoudas E S, Adamis A P, Cunnigham E T. et al . Pegaptanib for Neovascular Age-Related Macular Degeneration.  N Engl J Med. 2004;  351 2805-2816
    Search in Google Scholar
  • 41 Heidrich H, Harnisch J P, Ranft J. PGE1 bei seniler Maculadegeneration. Pilot-Studie.  Klin Monatsbl Augenheilkd. 1989;  194 282-284
    Search in Google Scholar
  • 42 Jonas J B, Degenring R F, Kreissig I. et al . Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomised study.  Eye. 2004;  19 163-170
    Search in Google Scholar
  • 43 Khan J C, Thurlby D A, Shahid H. et al . Smoking and age related macular degeneration: the number of packs years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation.  Br J Ophthalmol. 2006;  90 75-80
    Search in Google Scholar
  • 44 Kinos F, Roseilli G, Lamartina S. et al . Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.  Mol Vis. 2005;  11 366-373
    Search in Google Scholar
  • 45 Klaver D, Wolfs R, Vingerling J. et al . Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study.  Arch Ophthalmol. 1998;  116 653-658
    Search in Google Scholar
  • 46 Klein R, Klein B E, Jensen S C. et al . The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.  Ophthalmology. 1997;  104 7-21
    Search in Google Scholar
  • 47 Klein R J, Zeiss C, Chew E Y. et al . Complement factor H polymorphism in age-related macular degeneration.  Science. 2005;  308 385-389
    Search in Google Scholar
  • 48 Krishnaiah S, Das T, Nirmalan P K. et al . Risk factors for age-related macular degeneration: findings from the Andhra Pradesh eye disease study in South India.  Invest Ophthalmol Vis Sci. 2005;  46 4442-4449
    Search in Google Scholar
  • 49 Kryzstolik M G, Afshari M A, Adamis A P. et al . Prevention of experimental choroidal neovascularisation with intravitreal anti-vascular endothelial growth factor antibody fragment.  Arch Ophthalmol. 2002;  120 338-346
    Search in Google Scholar
  • 50 Kwak N, Okamoto N, Wood J M. et al . VEGF is major stimulator in model of choroidal neovascularization.  Invest Ophthalmol Vis Sci. 2000;  41 3158-3164
    Search in Google Scholar
  • 51 Ladewig M S, Ladewig K, Güner M. et al . Prostaglandin E 1 infusion therapy in dry age-related macular degeneration.  Prostaglandins, Leukotrienes and Essential Fatty Acids. 2005;  72 251-256
    Search in Google Scholar
  • 52 Lazic R, Gabric N. Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration.  Ophthalmology. 2007;  114 1179-1185
    Search in Google Scholar
  • 53 Macular photocoagulation study group . Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration.  Arch Ophthalmol. 1997;  115 741-747
    Search in Google Scholar
  • 54 Manzano R P, Peyman G A, Khan P. et al . Intravitreal bevacizumab did not appear toxic to the retina of New Zealand albino rabbits.  Retina. 2006;  26 257-261
    Search in Google Scholar
  • 55 Mares J A, Moeller S M. Diet and age-related macular degeneration: expanding our view.  Am J Clinical Nutrition. 2006;  83 733-734
    Search in Google Scholar
  • 56 Marschall J. The ageing retina: Physiology or Pathology.  Eye. 1987;  1 282-295
    Search in Google Scholar
  • 57 Martin R K, Laura A, Bleau L PN. et al . Electrophysiological findings after intravitreal bevacizumab (Avastin) treatment.  Retina. 2006;  26 270-274
    Search in Google Scholar
  • 58 Matsuoka M, Ogata N, Otsuji N. et al . Expression of pigment epithelium derived factor and vascular endothelial groeth factor in choroidal neovascular membranes and polypoidal choroidal vsculopathy.  Br J Ophthalmol. 2004;  88 809-815
    Search in Google Scholar
  • 59 Michels S, Rosenfeld P J, Puliafito C A. et al . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.  Ophthalmology. 2005;  112 1035-1047
    Search in Google Scholar
  • 60 Jose S. MIRA Study Group . Pulido: Multicenter prospective randomized, double-masked, placebo-controlled study of rheophereseis to teat nonexudativeage-related macular degeneration: interim anasysis.  Trans Am Pohthalmol Soc. 2002;  100 85-107
    Search in Google Scholar
  • 61 Mori K, Gehlbach P, Ando A. et al . Regression of ocular neovascularization in reponse to increased expression of pigment epithelium-derived factor.  Invest Ophthalmol Vis Sci. 2002;  43 2428-2434
    Search in Google Scholar
  • 62 Mukesh B N, Dimitrov P N, Leikin S. et al . Five-year incidence of age-related maculopathy: the Visual Impairment Project.  Ophthalmology. 2004;  111 1176-1182
    Search in Google Scholar
  • 63 Newsom R S, Mcalister J C, Saeed M. et al . Results 28 months following transpupillary thermotherapy for classic and occult choroidal neovascularization in patients with age-related macular degeneration.  Ophthalmic Surg Lasers Imaging. 2005;  36 94-102
    Search in Google Scholar
  • 64 Ng E WM, Adamis A P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.  Can J Ophthalmol. 2005;  40 352-368
    Search in Google Scholar
  • 65 Ogata N, Wada M, Otsuji T. et al . Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization.  Invest Ophthalmol Vis Sci. 2002;  43 1168-1175
    Search in Google Scholar
  • 66 Parfyonova Y V, Plekhanova O S, Tkachuk V A. Plasminogen activators in vascular remodelling and angiogenesis.  Biochem (Moscow). 2002;  67 139-156
    Search in Google Scholar
  • 67 Penfold P L, Madigan M C, Gillies M C. et al . Immunological and aetiological aspects of macular degeneration.  Prog Retin Eye Res. 2001;  20 385-414
    Search in Google Scholar
  • 68 Penn J S, Rajara Tnam V S, Collier R J. et al . The effect of an angiogenesis steroid on neovascularisation in a rat model of retinopathy of prematurity.  Invest Ophthalmol Vis Sci. 2001;  42 283-290
    Search in Google Scholar
  • 69 Pepper M S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis.  Arterioscler Thromb Vasc Biol. 2001;  21 1104-1117
    Search in Google Scholar
  • 70 Ramussen H, Chu K W, Campochiaro P. et al . Clinical protocol. An open-label, phase 1, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).  Hum Gene Ther. 2001;  12 2029-2032
    Search in Google Scholar
  • 71 Reich S, Fosnot J, Kuroki A. et al . Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.  Mol Vis. 2003;  9 210-216
    Search in Google Scholar
  • 72 Rosenfeld P J, Brown D M, Heier J S. et al . Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1419-1431
    Search in Google Scholar
  • 73 Russel S R, Slakter J S, Ho A C. et al . Anecortave acetate treatment of „dry” AMD to reduce risk of progression to „wet” AMD - the anecortave acetate risk reduction trial (AART).  Invest Ophthalmol Vis Sci. 2004;  45 E-Abstract 3134
    Search in Google Scholar
  • 74 Saishin Y, Saishin Y, Takahashi K. et al . VEGF-TRAP R 1R2 suppresses choroidal neovasculaization and VEGF-induced breakdown of the blood-retinal barrier.  J Cell Physiol. 2003;  195 241-248
    Search in Google Scholar
  • 75 Schmidt-Erfurth U, Scholtzer-Schrehard U, Cursiefen C. et al . Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.  Invest Ophthalmol Vis Sci. 2003;  44 4473-4480
    Search in Google Scholar
  • 76 Seddon J M, Cote J, Davis N. et al . Progression of age-related macular degeneration association with body mass index, waist circumference, and waist-hip ratio.  Arch Ophthalmol. 2003;  121 785-792
    Search in Google Scholar
  • 77 Seddon J M, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake.  Arch Ophthalmol. 2003;  121 1728-1737
    Search in Google Scholar
  • 78 Seddon J M, Rosner B, Sperduto R D. et al . Dietary fat and risk for advanced age-related macular degeneration.  Arch Ophthalmol. 2001;  119 1191-1199
    Search in Google Scholar
  • 79 Senger D R, Galli S J, Dvorak A M. et al . Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.  Science. 1983;  219 983-985
    Search in Google Scholar
  • 80 Shaker J, Avery R L, Heilweil G. et al . Electrophysiological and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).  Retina. 2006;  26 262-269
    Search in Google Scholar
  • 81 Spaide R, Sorenson J, Maranan L. Combined photodynamic therapy with vertiporfin and intravitreal triamcinolone acetonide for choroidal neovascularisation.  Ophthalmology. 2003;  110 1517-1525
    Search in Google Scholar
  • 82 Spaide R F. Rationale for Combination Therapies for choroidal Neovascularization.  Am J Ophthalmol. 2006;  141 149-156
    Search in Google Scholar
  • 83 Suzuma K, Takahara N, Suzuma I. et al . Characterization of protein kinase C beta isoform’s action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation and retinal neovascularisation.  Proc Natl Acad Sci USA. 2002;  99 721-726
    Search in Google Scholar
  • 84 Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.  Am J Ophthalmol. 1980;  90 810-816
    Search in Google Scholar
  • 85 TAP Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report 1.  Archives of Ophthalmology. 1999;  117 1329-1345
    Search in Google Scholar
  • 86 TAP Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report 2.  Archives of Ophthalmology. 2001;  119 198-207
    Search in Google Scholar
  • 87 Tielsch J M, Javitt J C, Coleman A. et al . The prevalence of blindness and visual impairment among nursing home residents in Baltimore.  N Engl J Med. 1995;  332 1205-1209
    Search in Google Scholar
  • 88 Tolentino M J. Intravitreal bevacizumab-enhanced Pegaptanib therapy for CNV in AMD.  Supplement to Retinal Physician. 2006;  1 15-17
    Search in Google Scholar
  • 89 Usui T, Ishida S, Yamashiro K. et al . VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.  Invest Ophthalmol Vis Sci. 2004;  45 368-374
    Search in Google Scholar
  • 90 Van Leeuwen R, Ikram M K, Vingerling J R. et al . Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study.  Invest Ophthalmol Vis Sci. 2003;  44 3771-3777
    Search in Google Scholar
  • 91 Van Leeuwen R, Klaver C C, Vingerling J R. et al . The risk and natural course of age-related maculopathy: follow-up at 6 œ years in the Rotterdam study.  Arch Ophthalmol. 2003;  121 519-526
    Search in Google Scholar
  • 92 Verteporfin in photodynamic therapy study group . Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2.  American Journal of Ophthalmology. 2001;  131 541-560
    Search in Google Scholar
  • 93 Wang J J, Foran S, Smith W. et al . Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort.  Arch Ophthalmol. 2003;  121 658-663
    Search in Google Scholar
  • 94 Weigand S J, Zimmer E, Nork T M. et al . VEGF Trap both prevents experimental choroidal neovascularization and causes regression of established lesions in non-human primates.  Invest Ophthalmol Vis Sci. 2005;  46 E-Abstract 1411
    Search in Google Scholar
  • 95 Werdich X Q, Penn J S. Src family kinases, new therapeutic targets for intervention of VEGF-mediated retinopathy.  Invest Ophthalmol Vis Sci. 2005;  46 E-Abstract 1426
    Search in Google Scholar
  • 96 Xia P, Aiello L P, Ishii H. et al . Characterization of vascular endothelial growth factor’s effect on activation of protein kinase C, its isoforms, and endothelial cell growth.  J Clin Invest. 1996;  98 2018-2026
    Search in Google Scholar

Prof. Dr. Albert J. Augustin

Augenklinik - Klinikum Karlsruhe

Moltkestraße 90

76133 Karlsruhe

Phone: ++ 49/7 21/9 74 20 01

Fax: ++ 49/7 21/9 74 20 09

Email: 106020.560@compuserve.com